BONE BIOLOGICS CORP (BBLG) Stock Price & Overview
NASDAQ:BBLG • US0980706008
Current stock price
The current stock price of BBLG is 1.4 USD. Today BBLG is up by 0.36%. In the past month the price increased by 23.25%. In the past year, price decreased by -65.57%.
BBLG Key Statistics
- Market Cap
- 2.52M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.76
- Dividend Yield
- N/A
BBLG Stock Performance
BBLG Stock Chart
BBLG Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BBLG. When comparing the yearly performance of all stocks, BBLG is a bad performer in the overall market: 93.57% of all stocks are doing better.
BBLG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBLG. No worries on liquidiy or solvency for BBLG as it has an excellent financial health rating, but there are worries on the profitability.
BBLG Earnings
BBLG Forecast & Estimates
7 analysts have analysed BBLG and the average price target is 22.64 USD. This implies a price increase of 1517.43% is expected in the next year compared to the current price of 1.4.
BBLG Groups
Sector & Classification
BBLG Financial Highlights
Over the last trailing twelve months BBLG reported a non-GAAP Earnings per Share(EPS) of -3.76. The EPS increased by 87.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.64% | ||
| ROE | -57.81% | ||
| Debt/Equity | 0 |
BBLG Ownership
BBLG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBLG
Company Profile
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Company Info
IPO: 2015-11-27
BONE BIOLOGICS CORP
2 Burlington Woods Dr Ste 100
Burlington MASSACHUSETTS US
Employees: 2
Phone: 13024977115
BONE BIOLOGICS CORP / BBLG FAQ
Can you describe the business of BONE BIOLOGICS CORP?
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Can you provide the latest stock price for BONE BIOLOGICS CORP?
The current stock price of BBLG is 1.4 USD. The price increased by 0.36% in the last trading session.
Does BONE BIOLOGICS CORP pay dividends?
BBLG does not pay a dividend.
What is the ChartMill technical and fundamental rating of BBLG stock?
BBLG has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of BONE BIOLOGICS CORP (BBLG) based on its PE ratio?
BONE BIOLOGICS CORP (BBLG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.76).
When does BONE BIOLOGICS CORP (BBLG) report earnings?
BONE BIOLOGICS CORP (BBLG) will report earnings on 2026-05-11.